CASI Pharmaceuticals, Inc. Intellectual Property Contracts & Agreements
7 Contracts & Agreements
- License Agreements (7 contracts)
- License and Development Agreement for CB-5339 by and between Cleave Therapeutics, Inc. and CASI Pharmaceuticals, Inc. dated March 5, 2021 (Filed With SEC on May 13, 2021)
- License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Talon Therapeutics, Inc (Filed With SEC on March 30, 2021)
- License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals Cayman, L.P (Filed With SEC on March 30, 2021)
- License Agreement, dated as of September 17, 2014, by and between CASI Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc (Filed With SEC on March 30, 2021)
- Supplementary Agreement to the Exclusive License Agreement effective as of September 29, 2020 (Filed With SEC on November 9, 2020)
- Exclusive License Agreement by and between CASI Pharmaceuticals, Inc. and Juventas Cell Therapy Ltd. effective June 15, 2019 (Filed With SEC on August 9, 2019)
- License Agreement By and between EntreMed, Inc. and Celgene Corporation. (Filed With SEC on May 10, 2005)
